Wealth Enhancement Advisory Services
VRTX icon

Wealth Enhancement Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,100
Closed -$217K – 3120
2024
Q3 		$217K Buy
+5,100
New +$2.45M ﹤0.01% 2402
2024
Q2 		– Sell
-1,400
Closed -$46.6K – 2710
2024
Q1 		$46.6K Sell
1,400
-3,100
-69% -$1.31M ﹤0.01% 2347
2023
Q4 		$152K Buy
+4,500
New +$1.66M ﹤0.01% 2129

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Wealth Enhancement Advisory Services's VRTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $2.31M and bringing the position to 45,889 shares worth $21.5M. The position accounts for 0.04% of the portfolio, ranked #416.

Wealth Enhancement Advisory Services first reported a position in VRTX in Q2 2017 and has held it in 23 quarters since. The position peaked at $47.4M in Q3 2024. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 45,889 shares of Vertex Pharmaceuticals worth $21.5M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 5,221 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.31M.
  • Vertex Pharmaceuticals made up 0.04% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #416 holding.
  • Wealth Enhancement Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 23 quarters since.
  • Wealth Enhancement Advisory Services's Vertex Pharmaceuticals position peaked at $47.4M in Q3 2024.
  • 484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.